SYFOVRE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SYFOVRE (SYFOVRE).
SYFOVRE (pegcetacoplan) is a complement inhibitor that binds to complement C3 and its activation fragment C3b, thereby inhibiting the cleavage of C3 into C3a and C3b and preventing downstream complement activation. This reduces inflammation and complement-mediated damage in geographic atrophy.
| Metabolism | Pegcetacoplan is a pegylated peptide that is not metabolized by cytochrome P450 enzymes; it is likely degraded into small peptides and amino acids. |
| Excretion | Primarily catabolized into small peptides and amino acids; renal clearance of free drug <1% of dose, biliary/fecal excretion negligible. |
| Half-life | 5.1 days (systemic circulation); following intravitreal injection, vitreous half-life supports monthly dosing intervals. |
| Protein binding | Approximately 90% bound to plasma proteins (primarily albumin); binding is reversible. |
| Volume of Distribution | 0.26 L/kg (central compartment), indicating limited extravascular distribution; primarily confined to ocular tissues after intravitreal injection. |
| Bioavailability | Intravitreal injection: 100% (direct administration into vitreous); systemic bioavailability negligible due to local delivery. |
| Onset of Action | Intravitreal injection: reduction in geographic atrophy lesion growth observed at 6 months; maximal effect by 12-24 months. |
| Duration of Action | Dosing interval: 25-60 days (every 25-60 days intravitreal injection); effect on lesion growth persists over 2 years. |
Intravitreal injection of 0.1 mL (2 mg) pegcetacoplan once every 25 to 60 days, as determined by the physician.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; data not available for GFR-based modifications. |
| Liver impairment | No dose adjustment required for hepatic impairment; Child-Pugh based modifications not established. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustments recommended for elderly patients; clinical studies included patients aged 65 and older. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SYFOVRE (SYFOVRE).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Due to minimal systemic absorption after intravitreal administration, transfer into breast milk is unlikely. Caution advised. M/P ratio not determined. |
| Teratogenic Risk | SYFOVRE (pegcetacoplan) is an intravitreal injection with negligible systemic absorption; however, based on its mechanism of complement inhibition, theoretical risks in pregnancy cannot be excluded. No human data in pregnancy; animal studies are lacking. Risk cannot be ruled out. In first trimester, potential for complement system interference; second and third trimesters, minimal systemic exposure suggests low risk. |
■ FDA Black Box Warning
Warning: Increased risk of endophthalmitis and retinal vasculitis (including retinal occlusive vasculitis), which may lead to severe vision loss. These events are typically associated with intravitreal injections.
| Serious Effects |
["Ocular or periocular infections","Active intraocular inflammation"]
| Precautions | ["Endophthalmitis and retinal vasculitis (including retinal occlusive vasculitis) – serious ocular adverse events requiring prompt treatment.","Intraocular inflammation may occur; monitor patients for signs such as pain, photophobia, or decreased vision.","Increased intraocular pressure (IOP) – transient IOP elevation may occur post-injection; monitor and manage appropriately.","Neovascular age-related macular degeneration – SYFOVRE is not indicated for neovascular AMD; use in patients with both GA and neovascular AMD has not been studied."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required due to minimal systemic exposure. Standard prenatal care is recommended. In case of inadvertent systemic exposure, monitor for complement-mediated adverse effects. |
| Fertility Effects | No human data on fertility; animal reproductive studies not conducted. Based on mechanism, no direct effect on fertility expected. |